Pharma BD Deal Intelligence
Warner-Lambert's $2.1B all-stock buy of Agouron delivered Viracept, an HIV protease inhibitor, plus Agouron's oncology discovery pipeline. A modest, complementary bolt-on rather than a transformative bet—closed May 1999, months before Pfizer's much larger move on Warner-Lambert itself.
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Warner-Lambert acquired Agouron Pharmaceuticals in an all-stock merger valued at approximately $2.1B, with each Agouron share exchanged for roughly $60 of Warner-Lambert stock. Announced in January 1999, the deal closed on May 17, 1999. It gave Warner-Lambert the HIV protease inhibitor Viracept (nelfinavir) and Agouron's oncology discovery pipeline.
40K US cases/yr · $4.5B US HIV/AIDS Rx Market (1999)
Warner-Lambert acquired Agouron Pharmaceuticals for $2.1B in 1999 to gain ownership of Viracept (nelfinavir), the leading HIV protease inhibitor. Agouron was a structure-based drug design pioneer founded in 1984 in La Jolla, California, that used X-ray crystallography to develop targeted antivirals.
Warner-Lambert sought Agouron's HIV franchise and structure-based drug design capabilities to complement its Parke-Davis pharmaceutical division. When Pfizer acquired Warner-Lambert in 2000, Agouron became a Pfizer subsidiary and its La Jolla campus became Pfizer's primary antiviral research center.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Warner-Lambert Company / Agouron Pharmaceuticals (this deal) | 1999 | $2.1B | 48 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Gilead Sciences Inc. / Pharmasset Inc. | 2011 | $11.2B | 98 |
| Abbott Laboratories / Alere Inc. | 2016 | $5.8B | 95 |
| bioMerieux SA / BioFire Diagnostics Inc. | 2013 | $485M | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 1999 deals · Infectious Disease deals